• Publications
  • Influence
Role of AMP-activated protein kinase in mechanism of metformin action.
Metformin is a widely used drug for treatment of type 2 diabetes with no defined cellular mechanism of action. Its glucose-lowering effect results from decreased hepatic glucose production andExpand
  • 4,551
  • 301
  • PDF
The mechanisms of action of PPARs.
The peroxisome proliferator-activated receptors (PPARs) are a group of three nuclear receptor isoforms, PPAR gamma, PPAR alpha, and PPAR delta, encoded by different genes. PPARs are ligand-regulatedExpand
  • 2,151
  • 117
  • PDF
Fibroblast growth factor 21 corrects obesity in mice.
Fibroblast growth factor 21 (FGF21) is a metabolic regulator that provides efficient and durable glycemic and lipid control in various animal models. However, its potential to treat obesity, a majorExpand
  • 762
  • 47
Metabolic syndrome: a clinical and molecular perspective.
The metabolic syndrome is a cluster of interrelated common clinical disorders, including obesity, insulin resistance, glucose intolerance, hypertension, and dyslipidemia (hypertriglyceridemia and lowExpand
  • 593
  • 26
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Fibroblast growth factor 21 (FGF21) is a recently discovered metabolic regulator. Exogenous FGF21 produces beneficial metabolic effects in animal models; however, the translation of theseExpand
  • 570
  • 26
  • PDF
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta.
We have demonstrated previously that cyclo-oxygenase-2 (COX2), the rate-limiting enzyme in the biosynthesis of prostaglandins (PGs), is essential for blastocyst implantation and decidualization.Expand
  • 553
  • 25
  • PDF
New drug targets for type 2 diabetes and the metabolic syndrome
  • D. Moller
  • Biology, Medicine
  • Nature
  • 13 December 2001
An insidious increase in features of the 'metabolic syndrome' — obesity, insulin resistance and dyslipidaemia — has conspired to produce a worldwide epidemic of type 2 insulin-resistant diabetesExpand
  • 946
  • 24
  • PDF
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes
Inhibitors of dipeptidyl peptidase-4 (DPP-4), a key regulator of the actions of incretin hormones, exert antihyperglycemic effects in type 2 diabetic patients. A major unanswered question concernsExpand
  • 398
  • 20
  • PDF
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.
The orphan nuclear receptor, peroxisome proliferator-activated receptor (PPAR) gamma, is implicated in mediating expression of fat-specific genes and in activating the program of adipocyteExpand
  • 623
  • 17
  • PDF
Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects*
The peroxisome proliferator-activated receptors (PPARs) include three receptor subtypes encoded by separate genes: PPARα, PPARδ, and PPARγ. PPARγ has been implicated as a mediator of adipocyteExpand
  • 381
  • 16